Bio-Techne has bought University of Minnesota-founded genome editing platform operator B-Mogen Biotechnologies to solidify a business relationship that dates to 2016.
B-Mogen Biotechnologies, a US-based genome editing services spinout of University of Minnesota, has been purchased by biotech and clinical diagnostics products supplier Bio-Techne for an undisclosed sum, StarTribune reported yesterday.
While terms were not disclosed, Bio-Techne confirmed it would directly fund the acquisition from its cash holdings.
Founded in 2015, B-Mogen Biotechnologies provides strategic support and other services for genomic engineering with the purpose of making drug development programs including gene and cell therapies more effective.
Services…